Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.

"Conflict of Interest M.F. has received research grants from Amgen, Biogen, Janssen, Pfizer and Takeda; consultancy fees from AbbVie, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Sandoz, Takeda and Thermo Fisher; and speakers’ fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda and Truvion Healthcare. B.G.F. has received consultancy fees from Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring, gIcare Pharma, Gilead Sciences, Given Imaging, GSK, Ironwood Pharma, Janssen Biotech [Centocor], JnJ/Janssen, Kyowa Hakko Kirin Co., Ltd, Lexicon, Lilly, Lycera BioTech, Mesoblast Pharma, Millennium, MSD, Nektar, Nestlé, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Roche/Genentech, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, VHsquared Ltd., Warner Chilcott, Wyeth, Zealand and Zyngenia; and grants and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech [Centocor], JnJ/Janssen, Millennium, Pfizer, Receptos, Roche/Genentech, Sanofi, Santarus, Tillotts and UCB Pharma; and is on the board of directors for Robarts Clinical Trials. J.P. has received consultancy fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GoodGut, GSK, Janssen, Origo, Pandion, Pfizer, Progenity, Robarts, Roche, Takeda, Theravance and Wassermann; speakers’ fees from AbbVie, Janssen and Takeda; and research funding from AbbVie and Pfizer. F.B. has received research grants from AbbVie, Amgen, Chiesi, Ipsen and MSD; and speakers’ and consultancy fees from AbbVie, Arena, Falk, Ferring, Janssen, MSD, Mundipharma, Pfizer, Takeda and Vifor Pharma. E.L. has received research grants from Janssen, Pfizer and Takeda; educational grants from AbbVie, Janssen, MSD and Takeda; speakers’ fees from AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer and Takeda; and consultancy fees from AbbVie; and participated in advisory boards with AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Pfizer and Takeda. O.D. has received speakers’ or consultancy fees from AbbVie, Ferring, Janssen, MSD, Mylan, Pfizer, Sandoz and Takeda. A.K. has received consultancy fees from Applied Molecular Transport, AstraZeneca, Boehringer Ingelheim, Galapagos, Genentech, Gilead Sciences, Glenmark, GSK, Hospira, Janssen, Kintai Therapeutics, Novartis, Pfizer, Roche and VHsquared Ltd. G.R.D. has received consultancy and/or speakers’ fees from AbbVie, ActoGeniX, AIM, Allergan, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo Technologies, Elan Pharmaceuticals, enGene, Falk, Ferring, Galapagos, Genentech, Gilead Sciences, Giuliani SpA, Given Imaging, Gossamer Bio, GSK, Janssen, Lilly, MSD, Neovacs, Novo Nordisk, Otsuka, PDL BioPharma, Pfizer, Progenity, Prometheus Laboratories, Robarts Clinical Trials, Salix, Schering-Plough, Seres/Nestlé, SetPoint, Shire, Takeda, Tillotts, UCB Pharma, Versant and Vifor Pharma; research grants from AbbVie, Falk, Given Imaging, Janssen, MSD and PhotoPill; and speaking honoraria from AbbVie, Ferring, MSD, Norgine, Shire, Tillotts, Tramedico and UCB Pharma. W.R.D., Y.P., W.-J.L., D.G., X.L., K.W. and J.K. are AbbVie employees and may own AbbVie stock and/or options."

"Funding This work was supported by Boehringer Ingelheim and AbbVie. Boehringer Ingelheim and AbbVie participated in the study design, research, analysis, data collection, interpretation of data, review and approval of the publication. AbbVie provided writing support for this publication. All authors had access to relevant data and participated in the drafting, review and approval of this publication. No honoraria or payments were made for authorship."

"Clinical trial registration number: NCT02513459"